Jagsonpal Pharmaceuticals Limited

NSE: JAGSNPHARM BSE: 507789 SECTOR: Healthcare - Pharmaceuticals & Biotechnology | Add Note | View Notes

240 3(-1%)

Volume

5L as on 23, Jun

Open

649

High

670

Low

637

243

VWAP

230

52 Week High

264

52 Week Low

155

Viand Research Rating

Quality Score

46/100

Growth Score

40/100

Valuation Score

50/100

Momentum Score

25/100

Analyst Recommendations

BUY/SELL

Hold | Buy | Strong Buy

Analyst Price Target

Market Cap (cr)

1,586

No. of Shares

6.71

P/E

74.48

P/B

9.18

Face Value

Div. Yield

Book Value (TTM)

CASH

DEBT

EPS (TTM)

ROE

12.33

ROCE

Profit Growth

Listing Date

01-Mar-00

Promoter Holding

67.89%

FII Holding

2.44%

DII Holding

0.22%

Price Chart

Price Performance

1 Week11%

1 Month10%

3 Months27%

6 Months31%

1 Year31%

YTD31%

Moving Average

5 Day SMA217

10 Day SMA213

20 Day SMA209

30 Day SMA208

50 Day SMA206

61 Day SMA202

80 Day SMA0

200 Day SMA0

PIVOT LEVEL

	Standard	Camarilla	Fibonacci	Woodie's
Resistance 3	245	227	237	245
Resistance 2	237	226	231	237
Resistance 1	230	224	227	229
Pivot Point	221	223	221	221
Support 1	214	221	215	214
Support 2	205	220	211	205
Support 3	198	218	205	198

Competitors/Peers

#	Symbol	MCAP	LTP	1W	1M	6M	1Y	P/E	Ind PE	Debt/Eq	NP Qtr Rs.Cr.
1	SUNPHARMA	4,56,655	1899	0%	2%	9%	21%	37	57.7	0.07	11509
2	DIVISLAB	2,43,196	9161	2%	8%	44%	51%	69	57.7	0	2568
3	TORNTPHARM	1,84,303	4846	2%	3%	12%	36%	72	57.7	1.79	2138
4	APOLLOHOSP	1,24,834	8650	1%	1%	12%	10%	58	57.7	0.9	2003
5	ZYDUSLIFE	1,12,897	1132	4%	2%	26%	13%	20	57.7	0.46	5124
6	CIPLA	1,11,346	1385	2%	5%	3%	12%	22	57.7	0.02	3862
7	LAURUSLABS	99,634	1844	3%	3%	75%	114%	0	57.7	0.48	890
8	DRREDDY	96,962	1151	2%	2%	11%	8%	20	57.7	0.2	4158
9	MAXHEALTH	96,646	985	1%	10%	8%	14%	0	57.7	0.32	1442
10	LUPIN	96,620	2113	1%	11%	8%	10%	23	57.7	0.29	5355
Load More

Shareholding Pattern (%)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021
Promoters	(0.51) 67.89%	(-0.21) 67.39%	(-0.11) 67.54%	(-0.11) 67.65%	(0.01) 67.77%	(-0.21) 67.82%	(-0.11) 67.98%	(0.01) 68.04%	(-0.41) 68.09%	(-0.21) 68.48%	(0.01) 68.72%	(0.01) 68.72%	(0.01) 68.72%	(0.01) 68.72%	(0.01) 68.72%	(0.01) 68.71%	(-1.61) 68.71%	(0.01) 70.34%	(0.01) 70.34%
FIIs	(0.31) 2.44%	(0.01) 2.12%	(0.01) 2.12%	(0.11) 2.17%	(0.01) 2.10%	(-0.21) 2.10%	(1.21) 2.30%	(0.41) 1.10%	(0.21) 0.73%	(0.21) 0.53%	(0.01) 0.38%	(0.31) 0.37%	(0.01) 0.10%	(0.01) 0.11%	(0.11) 0.13%	(0.01) 0.00%	(-0.21) 0.00%	(0.11) 0.20%	(0.01) 0.11%
DIIs	(0.11) 0.22%	(0.11) 0.15%	(0.01) 0.08%	(0.11) 0.05%	(0.01) 0.00%	(-0.11) 0.00%	(-0.71) 0.11%	(0.01) 0.84%	(0.01) 0.84%	(0.01) 0.82%	(0.01) 0.82%	(0.01) 0.82%	(0.01) 0.82%	(0.51) 0.77%	(-0.41) 0.28%	(0.01) 0.68%	(0.71) 0.67%	(0.01) 0.00%	(0.01) 0.01%
Public	29.44%	30.34%	30.25%	30.12%	30.11%	30.10%	29.63%	30.01%	30.33%	30.16%	30.07%	30.07%	30.34%	30.40%	30.85%	30.61%	30.61%	29.46%	29.54%
No. of Shareholders	26,264	24,895	24,653	22,899	21,085	18,471	15,633	15,748	16,282	15,785	16,041	13,782	14,084	14,535	14,952	16,194	17,100	20,031	14,353

Quarterly Results

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021
Sales	64.2	72.95	74.47	75.61	58.56	74.03	74.69	61.44	43.49	47.23	57.83	60.15	55.45	60	61	61	51.23	54	59	54.05
Sales Growth % (YoY)	-	-	-	-	-	-	-	-	-	-	-	-	-	10.4%	1.8%	12.1%	19.6%	-5%	5.6%	70.8%
Sales Growth % (QoQ)	-12%	-2%	-1.5%	29.1%	-20.9%	-0.9%	21.6%	41.3%	-7.9%	-18.3%	-3.9%	8.5%	-7.6%	-1.6%	-	19.1%	-5.1%	-8.5%	9.2%	-
Expenses	53.04	56.68	58.03	61.41	49.85	58.19	58.4	51.19	40.82	43.83	49.46	51.52	50.01	52	48	53	50.45	49	50	44.77
Operating Profit	11.16	16.27	16.44	14.2	8.71	15.84	16.29	10.25	2.67	3.4	8.37	8.63	5.44	9	13	7	0.78	6	9	9.28
OPM %	17.38	22.3	22.08	18.78	14.87	21.4	21.81	16.68	6.14	7.2	14.47	14.35	9.81	14	21	12	1.52	10	16	17.17
Other Income	3.17	0.9	3.03	2.83	2.56	25.51	1.65	-1.85	2.49	2.52	2.27	2	2.56	2	1	-3	0.37	2	0	0.82
Interest	0.25	0.26	0.27	0.25	0.26	0.26	0.23	0.22	0.22	0.23	0.22	0.15	0.2	0	0	0	0.06	0	0	0.11
Depreciation	2.32	2.39	2.39	2.35	2.31	2.41	2.34	1.07	0.4	0.41	0.46	0.39	0.48	0	0	0	0.65	0	0	0.28
Profit before tax	11.76	14.52	16.81	14.43	8.7	38.68	15.37	7.11	4.54	5.28	9.96	10.09	7.32	10	14	4	0.44	7	9	9.71
Tax %	25.43	24.59	25.22	25.23	24.48	17.27	25.44	25.04	21.59	24.81	25	25.87	23.5	21	24	24	31.82	24	30	29.45
Net Profit	8.76	10.95	12.57	10.8	6.58	31.99	11.46	5.33	3.55	3.96	7.47	7.48	5.6	8	10	3	0.31	5	7	6.85
Net Profit Growth % (QoQ)	-20%	-12.9%	16.4%	64.1%	-79.4%	179.1%	115%	50.1%	-10.4%	-47%	-0.1%	33.6%	-30%	-20%	233.3%	867.7%	-93.8%	-28.6%	2.2%	-
Net Profit Growth % (YoY)	33.1%	-65.8%	9.7%	102.6%	85.4%	707.8%	53.4%	-28.7%	-36.6%	-50.5%	-25.3%	149.3%	1706.5%	60%	42.9%	-56.2%	-	-	-	-
TTM Net Profit	43.08	40.9	61.94	60.83	55.36	52.33	24.3	20.31	22.46	24.51	28.55	31.08	26.6	21.31	18.31	15.31	19.16	18.85	13.85	0
EPS in Rs	1.31	1.64	1.89	1.62	0.99	4.82	1.73	0.81	0.54	0.6	1.14	1.14	0.85	1.19	1.59	0.45	0.05	0.83	1	2.61

Profit and Loss

	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013
Sales	287	269	209	237	218	188	159	167	127	144	143	138	144	166
Sales Growth %	6.9%	28.8%	-11.8%	8.8%	15.8%	18.5%	-5%	31.8%	-12%	0.3%	3.9%	-4%	-13.6%	-5.7%
Expenses	229	218	186	203	192	169	150	157	138	138	132	129	133	156
Operating Profit	58	51	23	34	26	19	9	9	-11	6	12	9	11	10
OPM %	20	19	11	14	12	10	5	6	-9	4	8	6	7	6
Other Income	10	28	9	2	3	4	3	1	0	13	1	0	0	0
Interest	1	1	1	0	0	1	1	1	1	3	5	4	5	5
Depreciation	9	8	2	1	2	1	1	1	0	2	3	3	3	3
Profit before tax	58	70	30	35	27	22	9	9	-12	14	4	2	3	3
Tax %	25	21	25	23	29	22	16	20	-1	18	20	30	16	28
Net Profit	43	55	22	27	19	17	8	7	-12	12	3	1	2	2
Net Profit Growth %	-21.8%	150%	-18.5%	42.1%	11.8%	112.5%	14.3%	158.3%	-200%	300%	200%	-50%	-	-
EPS in Rs	6.43	8.34	3.4	4.08	2.88	2.6	1.2	1.1	-1.76	1.81	0.5	0.18	0.32	0.28
Dividend Payout %	62	30	59	49	56	15	17	9	-2	2	8	22	62	72

Cash Flows

	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013
Cash from Operating Activity	47	55	35	47	7	28	11	31	-2	-3	9	4	8	12
Cash from Investing Activity	-36	-45	-25	-58	-26	-2	-11	-1	-3	41	-2	0	-1	-3
Cash from Financing Activity	-12	-12	-9	0	-18	-7	-1	-6	-1	-34	-6	-1	-4	-8
Net Cash Flow	-1	-2	2	-11	-36	19	0	24	-6	5	1	2	2	0

Balance Sheet

	Mar 2026	Sep 2025	Mar 2025	Sep 2024	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	263	240	227	184	174	146	120	109	98	91	85	97	85	82	85	85
Borrowings	8	9	9	10	9	6	0	7	5	4	8	8	38	39	36	33
Other Liabilities	32	37	29	51	21	30	31	35	31	28	23	25	22	19	22	21
Total Liabilities	317	299	278	258	217	195	164	164	147	136	130	143	159	154	156	153
Fixed Assets	85	90	94	99	9	24	23	26	22	22	21	22	52	52	56	58
CWIP	0	0	0	0	0	0	0	0	4	4	3	0	0	0	2	2
Investments	0	0	0	0	0	1	51	15	11	0	0	0	0	0	0	0
Other Assets	231	209	184	159	208	170	91	123	109	110	105	121	108	102	98	92
Total Assets	317	299	278	258	217	195	164	164	147	136	130	143	159	154	156	153

Delivery

Delivery Data: JAGSNPHARM

#	Date	214 23% 264	Value (Cr)	Q/T 58	Del 35	Del 9
1	4-Sep	242	2	38	48	1
2	3-Sep	243	7	46	44	3
3	2-Sep	237	1	31	61	1
4	1-Sep	240	2	29	45	1
5	31-Aug	241	6	33	45	3
6	28-Aug	239	2	30	50	1
7	27-Aug	237	2	30	56	1
8	26-Aug	242	2	32	45	1
9	25-Aug	241	1	22	52	1
10	24-Aug	241	5	36	46	2
11	21-Aug	237	2	31	54	1
12	20-Aug	233	2	36	51	1
13	19-Aug	230	1	30	57	1
14	18-Aug	231	6	40	39	2
15	17-Aug	234	2	39	56	1
16	14-Aug	227	1	24	44	0
17	13-Aug	230	1	29	49	1
18	12-Aug	225	3	48	64	2
19	11-Aug	231	1	32	49	1
20	10-Aug	233	1	31	43	1
21	7-Aug	231	2	33	49	1
22	6-Aug	238	4	36	39	2
23	5-Aug	240	3	53	52	2
24	4-Aug	236	3	39	45	1
25	3-Aug	235	4	46	46	2
26	31-Jul	231	10	44	18	2
27	30-Jul	236	352	91	5	17
28	29-Jul	230	2	33	48	1
29	28-Jul	224	1	25	61	1
30	27-Jul	230	2	31	42	1
31	24-Jul	222	1	25	46	0
32	23-Jul	218	1	17	36	0
33	22-Jul	220	1	32	47	1
34	21-Jul	222	1	28	46	0
35	20-Jul	223	1	30	45	1
36	17-Jul	224	1	9	48	0
37	16-Jul	227	3	28	33	1
38	15-Jul	224	1	29	48	1
39	14-Jul	226	1	23	52	0
40	13-Jul	230	1	26	56	1
41	10-Jul	233	1	25	39	1
42	9-Jul	232	2	32	42	1
43	8-Jul	229	3	32	41	1
44	7-Jul	239	5	31	24	1
45	6-Jul	237	5	44	34	2
46	3-Jul	237	6	41	20	1
47	2-Jul	235	5	37	29	1
48	1-Jul	238	14	49	20	3
49	30-Jun	238	260	106	5	13
50	29-Jun	230	10	48	22	2

Daily Market Cap

Date	Total Market Cap	Change	Chg %
04-Sep	1,586c	26c	1.60
03-Sep	1,611c	22c	1.36
01-Sep	1,590c	30c	1.86
31-Aug	1,620c	44c	2.80
27-Aug	1,576c	20c	1.24
26-Aug	1,596c	31c	1.98
25-Aug	1,565c	18c	1.16
24-Aug	1,583c	27c	1.74
21-Aug	1,556c	39c	2.59
19-Aug	1,517c	6c	0.40
18-Aug	1,523c	25c	1.63
17-Aug	1,548c	59c	3.94
14-Aug	1,489c	32c	2.10
13-Aug	1,521c	35c	2.33
12-Aug	1,487c	56c	3.63
11-Aug	1,543c	0	0
10-Aug	1,543c	31c	2.03
07-Aug	1,512c	70c	4.44
06-Aug	1,582c	58c	3.80
04-Aug	1,524c	21c	1.41
03-Aug	1,503c	14c	0.94
31-Jul	1,518c	63c	3.96
30-Jul	1,580c	69c	4.53
29-Jul	1,512c	47c	3.21
28-Jul	1,465c	49c	3.24
27-Jul	1,514c	0	0

Stock Checklist

Price is above from 52 week high low average: 78%

Stock is trading above all short term SMAs: YES

Stock is trading above all long term SMAs: YES

Stock is Consistently Improving Long Term: NO

FII purchased in last quarter: YES

Promoters are buying the stock: YES

Mutual Fund Holdings

Held by 2 fund scheme(s) across 1 fund house(s) as of Aug26 · Total value ₹0 Cr · 0 increasing / 0 decreasing · View in MF Pro →

Fund House	Schemes	Weight %	Change	Value (Cr)
Bandhan Mutual Fund	2	0.05%	-	0

Jagsonpal Pharmaceuticals Limited

Price Chart

Price Performance

Moving Average

PIVOT LEVEL

Competitors/Peers

Shareholding Pattern (%)

Quarterly Results

Profit and Loss

Cash Flows

Balance Sheet

Delivery

Daily Market Cap

Stock Checklist

Mutual Fund Holdings

Strategy Builder

Bulk Deals

Events

News

Exchange Filings

Annual Reports

Ratings & Research Reports

Concalls

Announcements